サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1318859

徐放性注射剤市場：用量、投与経路、エンドユーザー別-2023-2030年の世界予測

Sustained Release Injectables Market by Dosage, Route of Administration, End-User - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 190 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
徐放性注射剤市場：用量、投与経路、エンドユーザー別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 190 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

徐放性注射剤の世界市場は、2023年に21億5,686万米ドル、CAGR6.88%で大きく成長し、2030年には34億5,288万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の徐放性注射剤市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.徐放性注射剤の世界市場規模および予測は？

2.予測期間中、世界の徐放性注射剤市場を形成するCOVID-19の阻害要因と影響は？

3.徐放性注射剤の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.徐放性注射剤の世界市場における競争戦略は？

5.徐放性注射剤の世界市場における技術動向と規制の枠組みは？

6.徐放性注射剤の世界市場における主要ベンダーの市場シェアは？

7.徐放性注射剤の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 不適切な生活習慣の増加による主要な慢性疾患の有病率の増加
      • 小児および高齢者向けの需要の増加徐放性注射剤
      • 注射用製剤は経口製剤よりも優れた生物学的利用能を持っています
    • 抑制要因
      • 充填中のレオロジー変化、長期保管時の不安定性、および放出速度の調整不可
    • 機会
      • ナノテクノロジー、微細化、安定化プロセスなどの技術の進歩
      • 天然および化学合成生分解性素材のイントロダクション
    • 課題
      • 医薬品の価格が高く、熟練した専門家が不足している
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 徐放性注射剤市場用量別

  • 現場での配合物の形成
  • In situ形成ゲルシステム
  • In situ形成微粒子システム
  • リポソーム
  • マイクロカプセル
  • マイクロスフィア
  • 高分子ミセル

第7章 徐放性注射剤市場：投与経路別

  • 動脈間
  • 心臓内
  • 皮内
  • 筋肉内
  • 静脈内
  • 皮下

第8章 徐放性注射剤市場：エンドユーザー別

  • 診断研究所
  • 病院
  • 専門クリニック

第9章 南北アメリカの徐放性注射剤市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の徐放性注射剤市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの徐放性注射剤市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第13章 掲載企業一覧

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. SUSTAINED RELEASE INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2022 VS 2030
  • FIGURE 3. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2022 VS 2030 (%)
  • FIGURE 5. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
  • FIGURE 6. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
  • FIGURE 7. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. SUSTAINED RELEASE INJECTABLES MARKET DYNAMICS
  • FIGURE 9. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. SUSTAINED RELEASE INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. SUSTAINED RELEASE INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 5. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING GEL SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY IN SITU FORMING MICROPARTICLE SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY LIPOSOME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROCAPSULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY MICROSPHERE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY POLYMERIC MICELLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 13. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTERARTERIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRACARDIAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 45. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 48. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. AUSTRALIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 51. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 52. CHINA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 54. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 57. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. INDONESIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 60. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. JAPAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 63. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 64. MALAYSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 66. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. PHILIPPINES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 69. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. SINGAPORE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 72. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. SOUTH KOREA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 75. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. TAIWAN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 78. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. THAILAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 81. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. VIETNAM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 88. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. DENMARK SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 91. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. EGYPT SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 94. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. FINLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 97. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. FRANCE SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 100. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. GERMANY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 103. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. ISRAEL SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 106. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. ITALY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 109. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. NETHERLANDS SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 112. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. NIGERIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 115. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. NORWAY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 118. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. POLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 121. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. QATAR SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 124. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. RUSSIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 127. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SAUDI ARABIA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH AFRICA SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 133. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. SPAIN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 136. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWEDEN SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 139. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. SWITZERLAND SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 142. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. TURKEY SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED ARAB EMIRATES SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY DOSAGE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED KINGDOM SUSTAINED RELEASE INJECTABLES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. SUSTAINED RELEASE INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 151. SUSTAINED RELEASE INJECTABLES MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 152. SUSTAINED RELEASE INJECTABLES MARKET LICENSE & PRICING
目次
Product Code: MRR-43078BB92C97

The Global Sustained Release Injectables Market is forecasted to grow significantly, with a projected USD 2,156.86 million in 2023 at a CAGR of 6.88% and expected to reach a staggering USD 3,452.88 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Sustained Release Injectables Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Sustained Release Injectables Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Dosage, market is studied across In Situ Forming Formulations, In Situ Forming Gel System, In Situ Forming Microparticle Systems, Liposome, Microcapsule, Microsphere, and Polymeric Micelles. The Polymeric Micelles is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Interarterial, Intracardiac, Intradermal, Intramuscular, Intravenous, and Subcutaneous. The Intracardiac is projected to witness significant market share during forecast period.

Based on End-User, market is studied across Diagnostic Laboratories, Hospitals, and Specialty Clinics. The Hospitals is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.74% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Sustained Release Injectables Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Sustained Release Injectables Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Sustained Release Injectables Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Sustained Release Injectables Market?

4. What is the competitive strategic window for opportunities in the Global Sustained Release Injectables Market?

5. What are the technology trends and regulatory frameworks in the Global Sustained Release Injectables Market?

6. What is the market share of the leading vendors in the Global Sustained Release Injectables Market?

7. What modes and strategic moves are considered suitable for entering the Global Sustained Release Injectables Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Sustained Release Injectables Market, by Dosage, 2022 vs 2030
  • 4.3. Sustained Release Injectables Market, by Route of Administration, 2022 vs 2030
  • 4.4. Sustained Release Injectables Market, by End-User, 2022 vs 2030
  • 4.5. Sustained Release Injectables Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of major chronic diseases due to increasing adoption of poor lifestyle habits
      • 5.1.1.2. Rise in demand for paediatric and geriatric sustained release injectables
      • 5.1.1.3. Injectable preparations have a better bioavailability than oral preparations
    • 5.1.2. Restraints
      • 5.1.2.1. Rheological changes during filling, instability on long-term storage and nonadjustable release rate
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in technology such as nanotechnology, micronation, and stabilization process
      • 5.1.3.2. Introduction of natural and chemosynthetic biodegradable materials
    • 5.1.4. Challenges
      • 5.1.4.1. High cost of drugs and lack of skilled professionals
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Sustained Release Injectables Market, by Dosage

  • 6.1. Introduction
  • 6.2. In Situ Forming Formulations
  • 6.3. In Situ Forming Gel System
  • 6.4. In Situ Forming Microparticle Systems
  • 6.5. Liposome
  • 6.6. Microcapsule
  • 6.7. Microsphere
  • 6.8. Polymeric Micelles

7. Sustained Release Injectables Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Interarterial
  • 7.3. Intracardiac
  • 7.4. Intradermal
  • 7.5. Intramuscular
  • 7.6. Intravenous
  • 7.7. Subcutaneous

8. Sustained Release Injectables Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Sustained Release Injectables Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Sustained Release Injectables Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Sustained Release Injectables Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing